1
|
Ollivier L, Orione C, Champiat S, Lucia F, Misery L, Legoupil D, Pradier O, Bourbonne V, Kacperek C, Stefan A, Stefan D, Thillays F, Rio E, Vaugier L, Lesueur P, Supiot S, Schick U, Kao W. Réponses abscopales chez les patients atteints de mélanome métastatique : étude de cohorte multicentrique nationale. Cancer Radiother 2021. [DOI: 10.1016/j.canrad.2021.07.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
2
|
How C, Li L, Kao W. 63 Effect of 100-km ultramarathon on N-terminal pro-B-type natriuretic peptide variation. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehz872.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
The change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels follows strenuous endurance exercise-imposed paradox. Our previous reports showed significant body weight (BW) loss with dehydration was common in ultramarathon runners. The aim of this study is to investigate whether the dehydration and renin-angiotensin-aldosterone system activation possibly contribute to exercise-induced NT-proBNP release.
Methods
Twenty-six participants who finished a 100-km ultramarathon in Taiwan were enrolled. For each participant, blood samples and spot urine samples were collected one week before the race, as well as immediately and 24 hours after the finish. Body weight change was recorded to monitor the hydration status.
Results
Prolonged endurance exercise led to a substantial increase in NT-pro-BNP. Compared to pre-race values, NT-pro-BNP levels significantly increased immediately after the race (24.3 ± 20.2 to 402.9 ± 305.9 pg/mL, p < 0.05) and maintained the lasting high levels till 24 hours after the race finished (143.7 ± 126.1 pg/mL, p < 0.05). The fractional excretion of sodium values were all below 1% in three different time points. The 100-km ultramarathon resulted in significant BW loss, and elevated of renin and aldosterone levels. However, only 24 hours after the race, there was a positive significantly relationship between NT-proBNP and aldosterone levels, but negative significantly relationship between NT-proBNP and BW increase during the recovery phase.
Conclusions
Results of this study showed the mechanism of NT-proBNP release immediate following the race were multifaceted. However, during the recovery phase, rehydration might lead to the decrease of NT-proBNP in the volume depletion state.
Collapse
Affiliation(s)
- C How
- Taipei Veterans General Hospital, Taipei, Taiwan
| | - L Li
- Taipei Veterans General Hospital, Taipei, Taiwan
| | - W Kao
- Taipei Medical University Hospital, Taipei, Taiwan
| |
Collapse
|
3
|
Loiseau C, Barraux V, Berejny P, Batalla A, Austins H, Ollivier C, Piantino A, Nicolas C, Stefan D, Kao W, Silva M, Lerouge D. 34 Custom applicators made by 3D printer in brachytherapy: Experience of the F. Baclesse centre (Caen- France). Phys Med 2019. [DOI: 10.1016/j.ejmp.2019.09.115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
4
|
Lecornu M, Silva M, Barraux V, Stefan D, Kao W, Thariat J, Loiseau C. Applicateur numérique par impression tridimensionnelle en curiethérapie de contact. Cancer Radiother 2019; 23:328-333. [DOI: 10.1016/j.canrad.2019.03.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2019] [Revised: 03/01/2019] [Accepted: 03/07/2019] [Indexed: 11/17/2022]
|
5
|
Lesueur P, Lequesne J, Barraux V, Kao W, Geffrelot J, Habrand JL, Grellard JM, Émery E, Marie B, Thariat J, Stefan D. Radiochirurgie ou radiothérapie en conditions stéréotaxiques hypofractionnée pour les métastases cérébrales de cancer radiorésistant (mélanome et rein) : analyse comparative avec score de propension. Cancer Radiother 2018. [DOI: 10.1016/j.canrad.2018.07.088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Kao W, Gu R, Jia Y, Wei X, Fan H, Harris J, Zhang Z, Quinn J, Morand EF, Yang YH. A formyl peptide receptor agonist suppresses inflammation and bone damage in arthritis. Br J Pharmacol 2014; 171:4087-96. [PMID: 24824742 PMCID: PMC4243981 DOI: 10.1111/bph.12768] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2013] [Revised: 03/20/2014] [Accepted: 04/28/2014] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND AND PURPOSE Annexin A1 (AnxA1) is an endogenous anti-inflammatory protein and agonist of the formyl peptide receptor 2 (FPR2). However, the potential for therapeutic FPR ligands to modify immune-mediated disease has been little explored. We investigated the effects of a synthetic FPR agonist on joint disease in the K/BxN model of rheumatoid arthritis (RA) and RA fibroblast-like synoviocytes (FLS). EXPERIMENTAL APPROACH Arthritis was induced by injection of K/BxN serum at day 0 and 2 in wild-type (WT) or AnxA1(-/-) mice and clinical and histopathological manifestations measured 8-11 days later. WT mice were given the FPR agonist compound 43 (Cpd43) (6 or 30 mg·kg(-1) i.p.) for 4 days. Effects of AnxA1 and Cpd43 on RANKL-induced osteoclastogenesis were assessed in RAW 264.7 cells and human RA FLS and macrophages. KEY RESULTS Treatment with Cpd43 before or after the onset of arthritis reduced clinical disease severity and attenuated synovial TNF-α and osteoclast-associated gene expression. Deletion of AnxA1 in mice exacerbated arthritis severity in the K/BxN model. In vitro, Cpd43 suppressed osteoclastogenesis and NFAT activity elicited by RANKL, and inhibited IL-6 secretion by mouse macrophages. In human RA joint-derived FLS and monocyte-derived macrophages, Cpd43 treatment inhibited IL-6 release, while blocking FPR2 or silencing AnxA1 increased this release. CONCLUSIONS AND IMPLICATIONS The FPR agonist Cpd43 reduced osteoclastogenesis and inflammation in a mouse model of RA and exhibited anti-inflammatory effects in relevant human cells. These data suggest that FPR ligands may represent novel therapeutic agents capable of ameliorating inflammation and bone damage in RA.
Collapse
MESH Headings
- Animals
- Annexin A1/deficiency
- Annexin A1/metabolism
- Arthritis, Experimental/drug therapy
- Arthritis, Experimental/metabolism
- Arthritis, Experimental/pathology
- Arthritis, Rheumatoid/drug therapy
- Arthritis, Rheumatoid/metabolism
- Arthritis, Rheumatoid/pathology
- Bone and Bones/drug effects
- Bone and Bones/metabolism
- Bone and Bones/pathology
- Cells, Cultured
- Disease Models, Animal
- Inflammation/metabolism
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Phenylurea Compounds/administration & dosage
- Phenylurea Compounds/chemistry
- Phenylurea Compounds/pharmacology
- Pyrazoles/administration & dosage
- Pyrazoles/chemistry
- Pyrazoles/pharmacology
- Receptors, Formyl Peptide/agonists
- Receptors, Formyl Peptide/metabolism
- Structure-Activity Relationship
Collapse
Affiliation(s)
- W Kao
- Centre for Inflammatory Diseases, Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre, Monash UniversityClayton, Vic., Australia
- Department of Microbiology, Harbin Medical UniversityHarbin, China
| | - R Gu
- Centre for Inflammatory Diseases, Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre, Monash UniversityClayton, Vic., Australia
| | - Y Jia
- Centre for Inflammatory Diseases, Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre, Monash UniversityClayton, Vic., Australia
- Department of Rheumatology and Immunology, Peking University People's HospitalBeijing, China
| | - Xuemin Wei
- Centre for Inflammatory Diseases, Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre, Monash UniversityClayton, Vic., Australia
- Department of Rheumatology, The First Affiliated Hospital of Harbin Medical UniversityHarbin, China
| | - H Fan
- Centre for Inflammatory Diseases, Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre, Monash UniversityClayton, Vic., Australia
| | - J Harris
- Centre for Inflammatory Diseases, Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre, Monash UniversityClayton, Vic., Australia
| | - Zhiyi Zhang
- Department of Rheumatology, The First Affiliated Hospital of Harbin Medical UniversityHarbin, China
| | - J Quinn
- Prince Henry's Institute, Monash Medical CentreClayton, Vic., Australia
- Department of Biochemistry and Molecular Biology, Monash UniversityClayton, Vic., Australia
| | - E F Morand
- Centre for Inflammatory Diseases, Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre, Monash UniversityClayton, Vic., Australia
| | - Y H Yang
- Centre for Inflammatory Diseases, Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre, Monash UniversityClayton, Vic., Australia
| |
Collapse
|
7
|
Kao W, Wang C. Whole Brain Radiation Therapy With Simultaneously Integrated Boost for Patients With Multiple Brain Metastases. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.728] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
8
|
Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, Fedson S, Fisher P, Gonzales-Stawinski G, Martinelli L, McGiffin D, Smith J, Taylor D, Meiser B, Webber S, Baran D, Carboni M, Dengler T, Feldman D, Frigerio M, Kfoury A, Kim D, Kobashigawa J, Shullo M, Stehlik J, Teuteberg J, Uber P, Zuckermann A, Hunt S, Burch M, Bhat G, Canter C, Chinnock R, Crespo-Leiro M, Delgado R, Dobbels F, Grady K, Kao W, Lamour J, Parry G, Patel J, Pini D, Towbin J, Wolfel G, Delgado D, Eisen H, Goldberg L, Hosenpud J, Johnson M, Keogh A, Lewis C, O'Connell J, Rogers J, Ross H, Russell S, Vanhaecke J, Russell S, Vanhaecke J. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29:914-56. [PMID: 20643330 DOI: 10.1016/j.healun.2010.05.034] [Citation(s) in RCA: 1134] [Impact Index Per Article: 81.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2010] [Accepted: 05/31/2010] [Indexed: 12/26/2022] Open
|
9
|
Yao N, Kao W, Chao T, Hsieh R, Lin J, Su C, Lo S. A phase II study of gemcitabine and liposomal doxorubicin (Lipo-Dox) as first line chemotherapy in the treatment of metastatic breast cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.10688] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10688 Background: To determine the overall objective response rate (ORR) of Lipo-Dox plus Gemcitabine in patients with metastatic breast cancer. Patients and Methods: We are conducting an open-label, non-comparative phase II clinical trial in Simon’s 2-stage optimal design to assess the efficacy and the safety of the treatment with Gemcitabine (Gems) plus Liposomal Doxorubicin (Lipo-Dox) in patients with metastatic breast cancer. All eligible subjects received Lipo-Dox 25 mg/m2 intravenous infusion over 1 hr and follow by gemcitabine 800 mg/m2 intravenously (iv) over 30 minutes on day 1, and receive gemcitabine 800 mg/m2 intravenously (iv) over 30 minutes only on day 8 in a 21-day cycle. Results: Between July 2004 and December 2005, a total of 21 patients were enrolled in the study and total of 136 cycles of chemotherapy were delivered with a median of six per patients (range 1–16). 17 patients (80.8%) who had at least one post-treatment evaluation and exposed to at least two cycles of treatment were included in this report. Characteristics of the 17 patients: All females; median age 52 years (range 36 - 68); 16 pts had a performance status (PS) of 0 or 1 and 1 had a PS of 2 (ECOG scale); Histology: All metastatic breast cancer. The response assessment of the 17 patients: Complete response was observed in 2, partial response in 5, stable disease in 8, and progressive disease in 2 patients. Overall response rate was 41.17%. Major grade 3/4 hematological toxicities were neutropenia in 9 pts, thrombocytopenia in 2 pt and leukopenia in 5 pts. Peripheral neuropathy was noted in 1 patient (grade 2). Other toxicities occurred during the treatment cycles were all manageable or tolerable. Patient recruitment, treatment and follow-up are still ongoing. Conclusion: Liposomal Doxorubicin used in the regimen reduces the incidence of alopecia (hair loss) to grade 1 compare to the conventional doxorubicin. This study, with an overall response rate of 41.1% (CR+PR) and a rate of stable disease of 47.05%, has shown a good activity with mild and acceptable toxicities of Gemcitabine (Gems) plus Liposomal Doxorubicin (Lipo-Dox) regimen in patients with metastatic breast cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- N. Yao
- Tri-Service General Hospital, Taipei, Taiwan, Republic of China; MacKay Memorial Hospital, Taipei, Taiwan, Republic of China; Veterans General Hospital-Taipei, Taipei, Taiwan, Republic of China
| | - W. Kao
- Tri-Service General Hospital, Taipei, Taiwan, Republic of China; MacKay Memorial Hospital, Taipei, Taiwan, Republic of China; Veterans General Hospital-Taipei, Taipei, Taiwan, Republic of China
| | - T. Chao
- Tri-Service General Hospital, Taipei, Taiwan, Republic of China; MacKay Memorial Hospital, Taipei, Taiwan, Republic of China; Veterans General Hospital-Taipei, Taipei, Taiwan, Republic of China
| | - R. Hsieh
- Tri-Service General Hospital, Taipei, Taiwan, Republic of China; MacKay Memorial Hospital, Taipei, Taiwan, Republic of China; Veterans General Hospital-Taipei, Taipei, Taiwan, Republic of China
| | - J. Lin
- Tri-Service General Hospital, Taipei, Taiwan, Republic of China; MacKay Memorial Hospital, Taipei, Taiwan, Republic of China; Veterans General Hospital-Taipei, Taipei, Taiwan, Republic of China
| | - C. Su
- Tri-Service General Hospital, Taipei, Taiwan, Republic of China; MacKay Memorial Hospital, Taipei, Taiwan, Republic of China; Veterans General Hospital-Taipei, Taipei, Taiwan, Republic of China
| | - S. Lo
- Tri-Service General Hospital, Taipei, Taiwan, Republic of China; MacKay Memorial Hospital, Taipei, Taiwan, Republic of China; Veterans General Hospital-Taipei, Taipei, Taiwan, Republic of China
| |
Collapse
|
10
|
Abstract
The nicotine withdrawal syndrome was validated and characterized in the mouse using both somatic and affective measures after infusion with nicotine daily via subcutaneous minipumps. The influence of dose, duration of infusion, and repeated withdrawal as well as the contribution of genetic factors were investigated. We then characterized the contribution of nicotinic receptor and site mechanisms to withdrawal signs using various nicotinic antagonists. Our results showed that spontaneous nicotine withdrawal increased the number of somatic signs, decreased the time spent in open arms of the plus-maze test, and induced hyperalgesia. The effect was dose-dependent in all measures with no significant changes at the lowest dose of nicotine (6 mg/kg/day). Withdrawal signs were prominent shortly after pump removal and remained prominent through day 3 or 4. The results with the different antagonists (mecamylamine, dihydro-beta-erythroidine, and methyllycaconitine) suggest the involvement of several nicotinic subtypes such as alpha3beta4*, alpha4beta2*, and alpha7 in nicotine withdrawal. Increasing the duration of nicotine exposure (from 7 to 60 days) and the total nicotine exposure (increasing doses of infusing) augmented the severity of nicotine withdrawal signs. The withdrawal severity of nicotine differs between C57/BL and 129/SvEv inbred mice with nicotine withdrawal in C57 being more severe than in the 129 strain. In summary, our present results suggest that withdrawal from nicotine can be modulated by genetic factors, daily nicotine intake, duration of nicotine exposure, and withdrawal history. The present study demonstrates that our mouse nicotine withdrawal model will be useful for studying the pharmacological, biochemical, and genetic mechanisms involved in nicotine dependence.
Collapse
Affiliation(s)
- M I Damaj
- Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Box 980613, Richmond, VA 23298-0613, USA.
| | | | | |
Collapse
|
11
|
Pamboukian S, Hung E, McLeod M, Winkel E, Kao W, Costanzo M, Heroux A. The impact of bridging with ventricular assist device on rejection after orthotopic heart transplantation: is there a relationship? J Heart Lung Transplant 2002. [DOI: 10.1016/s1053-2498(01)00539-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
12
|
Tambur AR, Winkel E, Heroux A, Kao W, Pamboukian S, McLeod M, Parrillo JE, Costanzo MR. Flow panel reactive antibody monitoring following heart transplantation. Transplant Proc 2001; 33:3295-7. [PMID: 11750410 DOI: 10.1016/s0041-1345(01)02399-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- A R Tambur
- Heart Failure and Cardiac Transplant Program, Section of Cardiology, Rush Medical Center, Chicago, IL 60612, USA
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Chemmalakuzhy J, Costanzo MR, Meyer P, Piccione W, Kao W, Winkel E, Saltzberg M, Heroux A, Parrillo J. Hypotension, acidosis, and vasodilatation syndrome post-heart transplant: prognostic variables and outcomes. J Heart Lung Transplant 2001; 20:1075-83. [PMID: 11595562 DOI: 10.1016/s1053-2498(01)00299-6] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Abstract
BACKGROUND In recent years a syndrome characterized by hypotension, acidosis, and vasodilatation, which we have designated HAV syndrome, has been reported to occur more frequently after heart transplantation (HT), but its pathogenesis is unknown. METHODS We analyzed consecutive patients undergoing HT between January 1994 and June 1998 (aged 50 +/- 8 years; 87% male; 40% African American; ischemia time, 190 +/- 20 minutes; given triple immunosuppression without anti-lymphocyte antibodies) in 2 groups: 38 (54%) who developed HAV (systemic vascular resistance < or = 800 dines x sec x cm(-5) and serum bicarbonate < or = 20 mEq/liter) and 32 (46%) who did not. To identify causes of HAV, we compared 113 pre-HT donor and recipient variables, 28 peri-HT variables, and 46 post-HT variables between groups. We used Mann-Whitney, Fisher exact, and chi-squared tests to compare variables and to determine significance. RESULTS Univariate analysis showed that HAV patients had significantly greater recipient and donor weight (p = 0.000007 and 0.0017, respectively), longer ischemia times (p = 0.0052), pre-HT use of beta-blockers (p = 0.009), and longer waiting times for HT (p = 0.018). African-American patients had less HAV than Caucasians (p = 0.047). Patients with pre-HT mechanical circulatory assistance had less HAV than pharmacologically treated patients (p = 0.014). Multivariate analysis showed that recipient (p = 0.0004) and donor weight (p = 0.0394) and ischemia time (p = 0.0015) independently predicted HAV and correlated with HAV severity. Deaths at < or =30 days of HT occurred more in patients with (33%) than in those without (15%) HAV. CONCLUSIONS (1) Hypotension, acidosis, and vasodilatation after HT are associated with high mortality. (2) Recipient and donor weights and ischemia time are independent risk factors for HAV. (3) Pre-HT mechanical circulatory assistance and African-American race confer protection against HAV. (4) Because HAV risk factors can be altered, prevention may be possible. Further study is needed to identify the cellular and humoral mediators of HAV.
Collapse
|
14
|
Abstract
Patients with decompensated heart failure should be managed in an aggressive and proactive manner, using predominantly hemodynamic and end-organ function goals. This management is in contrast to the chronic maintenance therapy of patients with heart failure, where a neuroendocrine approach is indicated. Underlying anatomic targets for intervention should be sought aggressively and addressed. Patients who prove resistant to standard measures should be considered for early referral to heart transplant centers for more definitive measures, including evaluation for heart transplantation and mechanical circulatory support if necessary.
Collapse
Affiliation(s)
- W Kao
- Rush Heart Failure and Cardiac Transplant Program, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, USA
| | | |
Collapse
|
15
|
Pamboukian SV, Heroux A, Bartlett L, Delgado D, Meyer P, Winkel E, Kao W, Saltzberg M, Costanzo MR. Specialized, comprehensive care eliminates racial and gender differences in mortality between African American and Caucasian heart failure patients. J Heart Lung Transplant 2001; 20:232. [PMID: 11250445 DOI: 10.1016/s1053-2498(00)00519-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Affiliation(s)
- S V. Pamboukian
- Rush Presbyterian St. Luke's Medical Center, Chicago, IL, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Pamboukian SV, Heroux A, Bartlett L, Mcleod M, Meyer P, Winkel E, Kao W, Saltzberg M, Costanzo MR. Is outcome after heart transplantation influenced by ethnicity? A comparison of African Americans versus Caucasians. J Heart Lung Transplant 2001; 20:238. [PMID: 11250462 DOI: 10.1016/s1053-2498(00)00535-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Affiliation(s)
- S V. Pamboukian
- Rush Presbyterian St. Luke's Medical Center, Chicago, IL, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
|
18
|
Abstract
Although medical therapy, particularly with angiotensin-converting enzyme (ACE) inhibitors, has been demonstrated to prolong life in patients with chronic heart failure, the effect of standard medical therapy on sudden unexpected death in patients with heart failure is less well understood. Recent clinical trials have provided new insights into this growing problem. The impact of modern medical therapy for heart failure, including ACE inhibitors, beta-adrenergic antagonists, digoxin, calcium channel antagonists, and antiarrhythmic interventions will be discussed.
Collapse
Affiliation(s)
- W Kao
- Rush Heart Failure and Cardiac Transplant Program, Rush Medical College, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA.
| | | |
Collapse
|
19
|
Winkel E, Kao W, Fisher SG, Heroux AL, Johnson MR, Costanzo MR. Outpatient inotropic therapy in heart transplant candidates: should its use influence waiting list priority status? J Heart Lung Transplant 1998; 17:809-16. [PMID: 9730431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
BACKGROUND The use of outpatient intravenous inotropic therapy in heart transplant candidates is contentious. In addition to concerns about morbidity and mortality rates, the current United Network for Organ Sharing (UNOS) heart allocation system presently grants no waiting list priority status benefit to candidates who receive intravenous inotropic therapy in the outpatient setting (UNOS status 2), whereas identical therapy given in an intensive care unit setting does increase priority status (UNOS status 1). The goal of this study was to determine whether an increase in UNOS waiting list priority status is justified in heart transplant candidates receiving outpatient intravenous inotropic therapy by comparing the waiting list mortality of UNOS status 2 candidates on such therapy with that of UNOS status 2 candidates maintained on oral heart failure agents alone. METHODS This is a retrospective analysis of the pretransplantation outcomes of heart transplant candidates initially listed as UNOS status 2, comparing 29 candidates receiving intravenous outpatient inotropic therapy (group 1) to 109 candidates maintained on oral heart failure agents alone (group 2). RESULTS The waiting list mortality was not significantly different between the two groups (group 1=7% vs group 2=20%, p=.18); however, group 1 patients had greater morbidity rates while awaiting transplantation than group 2 patients. A greater percentage of group 1 than group 2 patients clinically deteriorated to UNOS status 1 while awaiting transplantation (45% vs 11%), resulting in more group 1 patients undergoing transplantation overall, (59% vs 33%, p=.01) and more group 1 than group 2 patients undergoing transplantation at a higher priority status, UNOS status 1 (76% vs 33%, p=.003). Group 1 patients had more pretransplantation heart failure admissions (1.2 vs 0.6 admissions/total waiting period, p=.02) and longer hospital stays (26+/-39 vs 8.8+/-16 days, p=.03), spent a greater percentage of their total waiting time hospitalized (7% vs 2%, p=.003), and were more likely than group 2 patients to receive intravenous inotropic therapy during hospitalization (70% vs 25%, p=.001). CONCLUSION This study suggests that heart transplant candidates who require maintenance outpatient intravenous inotropic therapy represent a subgroup of UNOS status 2 candidates with greater waiting list morbidity, but no greater waiting list mortality than candidates who can be maintained on oral heart failure agents alone. However, the current UNOS heart allocation system provides for this increased illness acuity by assigning a higher priority status when necessary. A larger, prospective study is necessary to determine whether a true difference in waiting list mortality rates exists and if an increase in priority status is justified for UNOS status 2 candidates requiring maintenance inotropic therapy.
Collapse
Affiliation(s)
- E Winkel
- Department of Medicine, Rush Presbyterian St. Luke's Medical Center, Chicago, Ill 60612, USA
| | | | | | | | | | | |
Collapse
|
20
|
Kao W, Costanzo MR. Prognosis determination in patients with advanced heart failure. J Heart Lung Transplant 1997; 16:S2-6. [PMID: 9229303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Affiliation(s)
- W Kao
- Department of Internal Medicine, Rush Medical College, Rush Heart Failure and Cardiac Transplant Program, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Ill 60612, USA
| | | |
Collapse
|
21
|
Kao W, Winkel EM, Johnson MR, Piccione W, Lichtenberg R, Costanzo MR. Role of maximal oxygen consumption in establishment of heart transplant candidacy for heart failure patients with intermediate exercise tolerance. Am J Cardiol 1997; 79:1124-7. [PMID: 9114780 DOI: 10.1016/s0002-9149(97)00062-3] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Maximal exercise oxygen consumption (VO2max) was measured in patients with chronic congestive heart failure undergoing evaluation for heart transplantation. Although VO2max correlated with survival for the group as a whole, it did not demonstrate survival discrimination for patients in the intermediate range (VO2max = 12 to 17 ml/kg/min) and should therefore not be used as a benchmark test for determination of appropriateness for cardiac transplantation in this group of patients.
Collapse
Affiliation(s)
- W Kao
- Rush Heart Failure and Cardiac Transplant Program, Department of Cardiovascular Surgery, Chicago, Illinois, USA
| | | | | | | | | | | |
Collapse
|
22
|
Kao W, Helpern JA, Goldstein S, Gheorghiade M, Levine B. Abnormalities of skeletal muscle metabolism during nerve stimulation determined by 31P nuclear magnetic resonance spectroscopy in severe congestive heart failure. Am J Cardiol 1995; 76:606-9. [PMID: 7677088 DOI: 10.1016/s0002-9149(99)80166-0] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
These data confirm the presence of abnormal skeletal muscle metabolic function in patients with chronic heart failure. These changes are independent of patient compliance and central hemodynamic response to conventional exercise, and may explain, in part, the marked decrease in exercise tolerance often observed in patients with chronic severe heart failure. The etiology of these abnormalities of metabolic function and nutritive flow remains uncertain. TNS may prove useful in further elucidation of the peripheral metabolic consequences of chronic heart failure.
Collapse
Affiliation(s)
- W Kao
- Henry Ford Heart and Vascular Institute, Department of Neurology, Henry Ford Hospital, Detroit, Michigan, USA
| | | | | | | | | |
Collapse
|
23
|
Abstract
Because of the increasing discrepancy between the number of identified candidates for heart transplantation and available donor organs, appropriate selection of patients for heart transplantation is critical. The establishment of a cardiac prognosis that is significantly worse than that following heart transplant is central in the determination of candidacy for transplantation. However, with recent improvements in heart failure management, prognosis must be considered a dynamic state involving periodic reassessment to ensure an individual's ongoing suitability for transplantation. There have been many descriptions of prognostic indexes in heart failure, but care must be used when extrapolating observations collected from patients with a broad range of conditions to those with end-stage disease. The contraindications to heart transplantation have also evolved with the increasing success of the transplant process. Many conditions that precluded patients from heart transplant in the past are no longer regarded as absolute. Despite less stringent conditions for recipient candidacy, the need to achieve optimal results with an increasingly valuable donor resource will necessitate careful scrutiny of the posttransplant implications of the various conditions currently regarded as contraindications to heart transplant. Determination of heart transplantation candidacy therefore continues to remain a highly individualized process, requiring clinical judgment and experience.
Collapse
Affiliation(s)
- W Kao
- Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, USA
| | | | | |
Collapse
|
24
|
Kao W, McGee D, Liao Y, Heroux AL, Mullen GM, Johnson MR, Costanzo MR. Does heart transplantation confer additional benefit over medical therapy to patients who have waited > 6 months for heart transplantation? J Am Coll Cardiol 1994; 24:1547-51. [PMID: 7930289 DOI: 10.1016/0735-1097(94)90153-8] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
OBJECTIVES This study compared the survival of patients with heart failure who have waited > 6 months for heart transplantation with that patients who undergo heart transplantation after a similarly prolonged waiting period. BACKGROUND There are little data describing outcome in patients with severe heart failure who have waited for extended periods of time on the heart transplant waiting list. METHODS Sixty-three consecutive patients who spent > 6 months on the heart transplant waiting list were examined. Mean (+/- SD) age was 53 +/- 9 years, mean left ventricular ejection fraction was 19 +/- 6%, and all were taking digoxin and diuretic and vasodilator agents. Patients who underwent transplantation during the follow-up period were censored from the pretransplantation analysis, and their survival was examined as part of the posttransplantation phase of the study. RESULTS Of the 63 original patients examined, 25 underwent transplantation, 10 during inotropic or mechanical circulatory support. The pretransplantation mortality rate was 6% at 6 months after the 6-month milestone on the waiting list, 12% at 12 months and 22% at 18 months. The posttransplantation mortality rate was 5% at 6 months, 10% at 12 months and 24% at 18 months. There were no differences in survival at any time between the two phases of the study. CONCLUSIONS Survival of patients who have survived > 6 months on the heart transplant waiting list is generally good. Although heart transplantation did not appear to confer additional survival advantage over medical therapy, a large proportion of the patients who underwent transplantation were critically ill at the time of transplantation and would undoubtedly have died of progressive heart failure had they not undergone transplantation. We conclude that heart transplantation should still be considered a therapeutic alternative in patients with heart failure even after a prolonged waiting period on the heart transplant waiting list.
Collapse
Affiliation(s)
- W Kao
- Loyola University Medical Center, Maywood, Illinois
| | | | | | | | | | | | | |
Collapse
|
25
|
Kao W, Jessup M. Exercise testing and exercise training in patients with congestive heart failure. J Heart Lung Transplant 1994; 13:S117-21. [PMID: 7947867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Affiliation(s)
- W Kao
- Heart Failure and Heart Transplant Service, Loyola University Medical Center, Maywood, IL 60153
| | | |
Collapse
|
26
|
Costanzo-Nordin MR, Winters GL, Fisher SG, O'Sullivan J, Heroux AL, Kao W, Mullen GM, Johnson MR. Endocardial infiltrates in the transplanted heart: clinical significance emerging from the analysis of 5026 endomyocardial biopsy specimens. J Heart Lung Transplant 1993; 12:741-7. [PMID: 8241211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
UNLABELLED To further elucidate the significance of endocardial infiltrates in heart transplant patients, the presence, frequency, and type of endocardial infiltrates were evaluated in 5026 endomyocardial biopsy specimens obtained from 200 heart transplant patients 0 to 75 months after heart transplantation. The relationship of endocardial infiltrates to immunologic, clinical, and demographic variables was then explored. Endocardial infiltrates were detected in 557 endomyocardial biopsy specimens (11%) from 117 heart transplant patients (58%) at 6.3 +/- 9.4 months (mean +/- SD; range, 0 to 49 months) after heart transplantation. Heart transplant patients with endocardial infiltrates were younger (p = 0.03), had a greater incidence of idiopathic dilated cardiomyopathy before heart transplantation (p = 0.05), and included a greater percentage of females (p < 0.05). Both total and treated rejection rates were significantly higher in patients with endocardial infiltrates versus those without endocardial infiltrates (p = 0.0001). Rejection on the subsequent endomyocardial biopsies was more often present in endocardial biopsy specimens with endocardial infiltrates than in those without endocardial infiltrates, both in the presence (37% versus 24%; p < 0.001) and absence (33% versus 19%; p < 0.0001) of concomitant findings of rejection. No association was identified between endocardial infiltrates and posttransplantation lymphoproliferative disorder, cytomegalovirus infection, Epstein-Barr virus infection, or cardiac allograft vasculopathy. Multivariate regression analysis confirmed that the occurrence of endocardial infiltrates is associated with rejection when adjustment is made for patient's age, gender, heart disease before transplantation, follow-up time, and number of endomyocardial biopsies after heart transplantation (p = 0.0001). CONCLUSIONS (1) Endocardial infiltrates may occur with or without associated endomyocardial biopsy findings of rejection.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
|
27
|
Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson M, Heroux A, Kao W, Mullen GM, Radvany R, Robinson J. HLA-DR incompatibility predicts heart transplant rejection independent of immunosuppressive prophylaxis. J Heart Lung Transplant 1993; 12:779-89. [PMID: 8241215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
To determine whether immunosuppressive prophylaxis reduces the effect of HLA-DR incompatibility on rejection, we compared clinical and immunologic variables of patients given horse antithymocyte globulin, OKT3, or no immunosuppressive prophylaxis. Median follow-up was 27 months. Groups were similar in race; preoperative HLA reactivity; ABO matching; number of HLA-A, -B, -C, and -DR mismatches; and rejection severity. Patients given immunosuppressive prophylaxis were younger (p = 0.04), had a greater frequency of preoperative ischemic disease (p = 0.03), and had a higher 6-month rejection rate (p = 0.02). A highly significant association was found between the number of mismatches at the HLA-DR locus and rejection severity (p = 0.005). Within the OKT3-based immunosuppressive prophylaxis group and the no immunosuppressive prophylaxis group a significant association was found between the number of HLA-DR mismatches and rejection severity (p = 0.01 and p = 0.009, respectively). A similar trend was identified in the group given horse antithymocyte globulin-based immunosuppressive prophylaxis. Logistic regression, used to identify independent predictors of rejection, showed that the number of HLA-DR mismatches and not the use or type of immunosuppressive prophylaxis is significantly associated with rejection (p = 0.0009). One-year patient survival was 83% in the group with two HLA-DR mismatches and 85% in the group with one or no HLA-DR mismatch. Thus the lower rejection rates in patients with one or no HLA-DR mismatch were not associated with a 1-year survival, which was better than that of patients with two HLA-DR mismatches. The potential benefit of HLA-DR matching on rejection and patient survival must be confirmed by larger prospective studies.
Collapse
|
28
|
Singh JP, Yueh FY, Kao W, Cook RL. Study of high-temperature multiplex HCl coherent anti-Stokes Raman spectroscopy spectra. Appl Opt 1993; 32:894-898. [PMID: 20802764 DOI: 10.1364/ao.32.000894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
A feasibility study of temperature measurement with multiplex HCl coherent anti-Stokes Raman spectroscopy (CARS) is investigated. The HCl CARS spectra of a 100% HCl gas sample are recorded in a quartz sample cell placed in a furnace at 1 atm pressure and at different temperatures. The nonlinear susceptibility of HCl (chi(nr)(HCl)), which is measured with the present CARS experimental setup, is reported. The experimental spectra are fit by using a library of simulated HCl CARS spectra with a least-squares-fitting program to infer the temperature. The inferred temperatures from HCl CARS spectra are in agreement with thermocouple temperatures.
Collapse
|
29
|
Johnson MR, Mullen GM, O'Sullivan EJ, Liao Y, Heroux AL, Kao W, Pifarre R, Costanzo-Nordin MR. Risk/benefit ratio of perioperative OKT3 in cardiac transplantation. Transplant Proc 1993; 25:1149-51. [PMID: 8442068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
This study shows that perioperative OKT3 provides no benefit in terms of the time of onset or frequency of rejection or patient survival. However, it does result in an increased incidence of infection, particularly CMV infection. Thus, the risk/benefit ratio of perioperative OKT3 does not appear favorable. However, a multicenter, randomized trial including a larger number of patients and longer patient follow-up will be required to definitively answer the question.
Collapse
Affiliation(s)
- M R Johnson
- Department of Medicine, Loyola University Medical Center, Maywood, Illinois 60153
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Gheorghiade M, Schultz L, Tilley B, Kao W, Goldstein S. Natural history of the first non-Q wave myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. Am Heart J 1991; 122:1548-53. [PMID: 1957749 DOI: 10.1016/0002-8703(91)90270-r] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Despite extensive investigation, the prognostic significance of the first non-Q wave acute myocardial infarction (AMI), when compared with Q wave AMI, remains controversial. The placebo arm of the Beta-Blocker Heart Attack Trial (BHAT) provides a unique opportunity to compare the long-term cardiac events in patients suffering from their first and uncomplicated Q wave or non-Q wave AMI. Of a total 3837 patients enrolled in the BHAT, 3375 were classifiable in terms of appearance or absence of Q waves during the prerandomization period. Of these, 1444 patients with their first AMI were randomized to placebo. Of these, 1186 experienced a Q wave AMI; the remaining 258 suffered a non-Q wave AMI. At 36 months of follow-up, the mortality was 8.4% in the Q wave AMI group and 7.4% in the non-Q wave AMI group. Sudden death was 5.4% in the Q wave AMI group and 4.7% in the non-Q wave AMI group. The reinfarction rate was 5.5% in the Q wave AMI patients and 7.4% in the non-Q wave AMI patients. More patients developed angina (44.6%) in the non-Q wave AMI group compared with 35.2% in the Q wave AMI group. Despite similar long-term cardiac event rates within the two groups, the 1-year mortality rate for patients with Q wave AMI appeared higher than in the non-Q wave AMI group, 5.2% versus 3.1%, respectively. In contrast, the rate of reinfarction appeared higher at the 12-month follow-up period in the non-Q wave AMI group, 4.7% versus 3.4%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)c
Collapse
Affiliation(s)
- M Gheorghiade
- Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI 48202
| | | | | | | | | |
Collapse
|
31
|
|
32
|
Abstract
Although the beneficial effects of long-term therapy with beta-adrenergic blocking agents in patients recovering from acute myocardial infarction (AMI) are established, the effect of this therapy on the cardiac event rate in patients recovering from a non-Q-wave AMI is unknown. This post hoc analysis of the Beta Blocker Heart Attack Trial (BHAT) evaluates the effects of daily administration of propranolol 180 or 240 mg/day after non-Q-wave AMI. The study population consisted of 601 patients with enzymatically proven non-Q-wave AMI, which represented 17% of the BHAT patients. Of these, 310 patients were randomized to receive propranolol and 291 patients to placebo. There were no significant baseline differences between groups. The median follow-up was 24.6 months. Mortality was 7.8% (sudden death 4.8%) in the propranolol group and 7.9% (sudden death 4.8%) in the placebo group (p greater than 0.99, log rank test). Reinfarction rate was 7.4% in the propranolol group and 6.5% in the placebo group (p greater than 0.63, log rank test). The need for coronary bypass surgery was similar in the 2 groups. However, more patients randomized to placebo developed angina. In this post hoc group analysis of the BHAT, propranolol was not shown to be beneficial in reducing the cardiac event rate in patients recovering from a non-Q-wave AMI.
Collapse
Affiliation(s)
- M Gheorghiade
- Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan 48202
| | | | | | | | | |
Collapse
|
33
|
Abstract
To correlate cardiac event rate with infarct location on the electrocardiogram in patients recovering from a non-Q-wave acute myocardial infarction (AMI), 135 consecutive patients with enzymatically proven non-Q-wave AMI were followed prospectively for a median of 9.9 months. Of these, 65 patients were classified as having had an anterior non-Q-wave AMI, defined as new ST- or T-wave changes, or both, in leads V1 through V4 (group 1). The remaining 70 patients were classified as having had inferior or lateral non-Q-wave AMI, or both, defined as ST- or T-wave changes in 2 consecutive leads (II, II aVF; II and aVL or V5 and V6) (group 2). At baseline group I was older and had a higher incidence of previous AMI than group 2. After adjusting for baseline variables, the patients in group I had a 29% reinfarction and 32% mortality rate, which was significantly higher (p less than 0.002 for both) when compared to group 2, which had a reinfarction and mortality rate of 8 and 9%, respectively. Patients with anterior non-Q-wave AMI are at very high risk for developing a major cardiac event very soon after the index AMI. This high risk is probably related to a larger area of residual ischemic but viable myocardium in the infarct-related artery when compared to inferolateral non-Q-wave AMI.
Collapse
Affiliation(s)
- W Kao
- Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan 48202
| | | | | | | |
Collapse
|
34
|
Kao W, Gheorghiade M, Hall V, Goldstein S. Relation between plasma norepinephrine and response to medical therapy in men with congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. Am J Cardiol 1989; 64:609-13. [PMID: 2782251 DOI: 10.1016/0002-9149(89)90488-8] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
This study examines the relation between the change in clinical status and the change in plasma norepinephrine concentration in patients with congestive heart failure (CHF) receiving standard medical therapy. Hemodynamic measurements in 11 patients with CHF (ejection fraction 19 +/- 4%) were obtained before and immediately after the administration of digoxin and angiotensin-converting enzyme inhibitors. Patients were then followed for 1 year. Clinical status was determined using the Boston Clinical Heart Failure scoring system. Of the 11 patients, 6 demonstrated significant clinical improvement after therapy, based on the Boston score, over a 1-year period. Five patients did not respond to therapy: 4 died and the remaining patient had worsening CHF. There was no difference between responders and nonresponders in either baseline hemodynamics or acute response to the administration of digoxin and an angiotensin-converting enzyme inhibitor. In the patients who improved, plasma norepinephrine decreased from 706 +/- 235 to 545 +/- 223 pg/ml (p = 0.08) after 1 year of medical therapy. In patients whose CHF worsened or who died, plasma norepinephrine increased from 715 +/- 275 at baseline to 1,237 +/- 671 pg/ml at their last measurement (p = 0.06). Although at baseline the plasma norepinephrine levels were similar in both groups of patients, a significant difference between responders and nonresponders was observed at final follow-up (p less than 0.002). Change in plasma norepinephrine correlated with change in CHF score (r = 0.79, p less than 0.004). Thus, in patients with CHF, serial measurements of plasma norepinephrine correlate with changes in clinical status.
Collapse
Affiliation(s)
- W Kao
- Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan 48202
| | | | | | | |
Collapse
|
35
|
Helpern JA, Kao W, Gross B, Kensora TG, Welch KM. Interleaved 31P NMR with transcutaneous nerve stimulation (TNS): a method of monitoring compliance-independent skeletal muscle metabolic response to exercise. Magn Reson Med 1989; 10:50-6. [PMID: 2755333 DOI: 10.1002/mrm.1910100105] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
31P NMR spectroscopy was used to monitor the metabolic response of the tibialis anterior muscle group to transcutaneous nerve stimulation of the peroneal nerve at a rate of 4 Hz for 5 min in human volunteers (n = 8). It is demonstrated that this technique can be used as a method of investigating effort-free and compensation-independent skeletal muscle exercise.
Collapse
Affiliation(s)
- J A Helpern
- Department of Neurology, Henry Ford Hospital, Detroit, Michigan 48202
| | | | | | | | | |
Collapse
|
36
|
Abstract
1. Three isozymes of pancreatic alpha-amylase, PPA 1, PPA 2, and PPA 3, were observed in a porcine population of 50 animals. 2. Isozyme PPA 2 was common to each pancreas. 3. Three phenotypic patterns were described as: (A) consisting of PPA 2 alone (20%); (B) consisting of PPA 1 and PPA 2 (78%); and (C) consisting of all three forms (2%). 4. Amylase isozymes were separated by anion exchange chromatography using DE53. 5. Individual isozymes corresponded to one of the three isozymes found in pancreatin. 6. Individual isozymes were inhibited equally by an amylase inhibitor from wheat. 7. Differences in amylase isozymes were attributed to genetically controlled mechanisms and not to artifacts of isolation.
Collapse
Affiliation(s)
- D H Strumeyer
- Department of Biochemistry and Microbiology, Rutgers, State University of New Jersey, New Brunswick 08903
| | | | | | | |
Collapse
|
37
|
Deshmukh DR, Kao W, Mason M, Maassab HF, Baublis JV. Serum enzyme alterations in arginine-deficient, influenza-infected ferrets: a potential animal model of Reye's syndrome. Enzyme 1982; 27:52-7. [PMID: 7067689 DOI: 10.1159/000459022] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Young male ferrets developed hyperammonemia and encephalopathy soon after eating a diet lacking arginine. Because of this characteristic and their known susceptibility to influenza infections, they were further tested as an animal model for Reye's syndrome (RS), a childhood disorder which sometimes develops following influenza and which is characterized in part by encephalopathy, hyperammonemia, and elevated serum transaminase levels. Either the deficiency or infection alone resulted in minor elevations of serum ornithine carbamyl transferase (S-OCT) activities and together resulted in substantial elevations. These and associated alterations are discussed in relationship to the metabolic disorders occurring in RS.
Collapse
|
38
|
Kao W, Chou KL. CRP, immunologically cross-reacting protein of prolyl hydroxylase. Its role in assembly of active pro-yl hydroxylase and cellular localization in L-929 fibroblasts. Arch Biochem Biophys 1980; 199:147-57. [PMID: 6243906 DOI: 10.1016/0003-9861(80)90267-2] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
39
|
Kao W, Strike DP. Synthesis of (+)-11-deoxy-15-ethynyl prostaglandins. Prostaglandins 1978; 16:467-71. [PMID: 725079 DOI: 10.1016/0090-6980(78)90226-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
This article describes the preparation of (+)-11-deoxy-15-ethynyl prostaglandins (1 & 16). The key step involves a conjugate addition of the substituted 1-lithio-1-oct-1-ene (2) to the cyclopentenone (3 & 12) to furnish 11-deoxy-prostaglandin skeleton in a simple fashion. Of particular interest in this synthesis is the preparation of alkyl side chain (7) which was achieved in an efficient three-step synthesis starting from the readily available beta-iodo vinyl ketone (4).
Collapse
|
40
|
Kao W, Rees RW. Synthesis of (+)-16-thioketal and 16-keto prostaglandins. Prostaglandins 1978; 16:461-5. [PMID: 725078 DOI: 10.1016/0090-6980(78)90225-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
41
|
|
42
|
Kao W. [Radioautographic studies on the incorporation of S35-labeled Na2SO4 in the extremities of the axolotl during regeneration and following irradiation]. Shi Yan Sheng Wu Xue Bao 1965; 10:285-98. [PMID: 5296122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|